Filer Snapshot

ELI LILLY & Co

CIK 0000059478. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

341

Latest filing

30 Jul 2026

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13D/G stake for Scribe Therapeutics, Inc.. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13D/G history Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

Scribe Therapeutics, Inc.

23 Jul 2026 · 7.3% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Schedule 13D/G

SCHEDULE 13D filed on 30 Jul 2026 for CIK 0000059478.

View source filing
Listed symbols
LLY on NYSE
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

Forms 3/4/5 positions$135.45M

Reporting-owner positions with enough filing detail to estimate value.

Forms 3/4/5 position value

3/4/5
$135.45M

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

AKTS

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

AKTSQ Scribe Therapeutics, Inc.

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

PRQR IMCR
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Pharmaceutical Preparations (Office of Life Sciences)
Business address
Lilly Corporate Ctr, Drop Code 1094, Indianapolis, IN, 46285
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Incorporated in
IN
Fiscal year end
31 December
Former names on EDGAR
LILLY ELI & CO (to 25 Oct 2019), LILLY ELI & CO ET AL (to 14 Oct 1994)

Filer intelligence

What SEC filings say about ELI LILLY & Co

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • 4 recent 13D/G stake rows found; top row is Scribe Therapeutics, Inc. at 7.3% ownership.
  • Forms 3/4/5 show insider context for AKTS worth $135.45M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes 4 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 3 rows

Officer, director, and 10% owner holdings or transactions.

Open

13D/G large-stake context

Scribe Therapeutics, Inc.

23 Jul 2026 · Common stock, $0.001 par value per share

7.3%
Issuer page 13D/G history

PRQR

26 Jun 2026 · Ordinary Shares, nominal value 0.04 EUR per share

16%
Issuer page 13D/G history

AKTSQ

12 Jan 2026 · Common Stock, $0.0001 par value per share

12%
Issuer page 13D/G history

IMCR

30 Sep 2025 · Ordinary Shares

0%
Issuer page 13D/G history

Forms 3/4/5 insider context

AKTS

12 Jan 2026 · 10% owner

$135.45M
Issuer page Owner page

SCTX

23 Jul 2026 · 10% owner

Issuer page Owner page

SGTX

11 Aug 2023 · 10% owner

Issuer page Owner page

Latest update

What changed recently for ELI LILLY & Co

New filing available

Latest Schedule 13D/G period: 23 Jul 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

30 Jul 2026

Page type

Filer profile

Latest period

23 Jul 2026

Schedule 13D/G context is visible from filings filed on 30 Jul 2026.

Open filer profile Browse recent public updates

Benchmark Context

Benchmark context for this company

ELI LILLY & Co has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest Schedule 13D/G period: 23 Jul 2026. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 30 Apr 2026.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0000059478 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
341
First seen
30 Jan 2024
Latest filing
30 Jul 2026
Entity
Company

Observed form types

10-K 10-Q 3 4 4/A SCHEDULE 13D SCHEDULE 13G SCHEDULE 13G/A

CIK-linked evidence first

ELI LILLY & Co SEC filings ELI LILLY & Co 13D/G history ELI LILLY & Co owner filings ELI LILLY & Co insider transactions ELI LILLY & Co company facts Open SEC filing index

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 12 of 341 SEC filings for ELI LILLY & Co.

Open full filing history
SCHEDULE 13D

SCHEDULE 13D filing

Filing date
30 Jul 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
24 Jul 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
24 Jul 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
21 Jul 2026
Reporting date
20 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
21 Jul 2026
Reporting date
20 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
21 Jul 2026
Reporting date
20 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
21 Jul 2026
Reporting date
20 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
16 Jun 2026
Reporting date
15 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
16 Jun 2026
Reporting date
15 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
16 Jun 2026
Reporting date
15 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
16 Jun 2026
Reporting date
15 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
11 Jun 2026
Reporting date
10 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .